RE:RE:RE:RE:Anakinra Attenuates Glioblastoma AggressivenessYes, good stuff, poof. So why did Bioasis drop all discussion of the most valuable uses for xB3? Do you have a theory for that?
Why did the corporate presentation emphasize EGF over xB3? (The Cresence EGF stuff is valued at around CDN $250,000 under the terms of this deal. (6 million shares x CDN $0.04)
Can you start with a short discussion of xB3-001 and the leak of the Ellispses deal that was later declared dead? Do you think that Bioasis "shelved" a deal until the "merger" was completed?
Do you think that Biodexa gets to keep the xB3 platform?
And can you make a case for Bioasis shareholders benefitting from their current loss of 75% of the value of their shares over the last month, and how the 4¢ share exchange can result in a win for Bioasis shareholders? Can the case for a win be made? (Discuss Biodexa's future funding needs and possible serious dilution.)
Do you think that the 75% ownership of Biodexa by LT and The Placee is a threat to the interests of the former Bioasis and Midatech shareholders?
Would you ordinarily support a deal like this with ownership and control going so overwhelmingly into private hands?
Would you advise going long on Midatech/Biodexa?
Would you like to see an investigation of the deal take place?
JD